Articles From: BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference to Biogen Idec Receives Notification of PDUFA Date Extension for Plegridy™ (Peginterferon Beta-1a)


RALEIGH, N.C. , Sept.
Sign-up for BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference investment picks
2014/2/10
Proceeds support BDSI's complete execution of anticipated 2014 commercial launch plans for BUNAVAIL™ and funding of Clonidine Topical Gel NDA program RALEIGH, N.C. , Feb.
Sign-up for BioDelivery Sciences to Raise $60 Million in Registered Direct Offering From Institutional Investors investment picks
2013/10/24
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1062429&ProfileId=051205&sourceType=1 FREDERICK, MD --
Sign-up for BioElectronics Corporation: Letter to Shareholders investment picks
2013/9/25
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0900438001&sourceType=1 http://www.ccnmatthews.com/logos/20100204-be200.jpg TORONTO, ONTARIO --
Sign-up for BioExx Announces Delisting Review Process Initiated by the Toronto Stock Exchange investment picks
2013/11/5
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0909358001&sourceType=1 http://www.ccnmatthews.com/logos/20100204-be200.jpg TORONTO, ONTARIO --
Sign-up for BioExx Announces Novel Food Status & Company Sale Process Update investment picks
2013/10/1
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0901887001&sourceType=1 http://www.ccnmatthews.com/logos/20100204-be200.jpg TORONTO, ONTARIO --
Sign-up for BioExx Specialty Proteins Announces CCAA Filing investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0895049001&sourceType=1 http://www.ccnmatthews.com/logos/20100204-be200.jpg TORONTO, ONTARIO --
Sign-up for BioExx Specialty Proteins Announces Change in Management investment picks
2014/3/27
DENVER , March 27, 2014 /PRNewswire/ --  BIOFUEL ENERGY CORP.
Sign-up for BioFuel Energy Moves To Preserve Net Operating Loss Carryforwards By Adopting Shareholder Rights Plan investment picks
2014/3/28
DENVER , March 28, 2014 /PRNewswire/ --  BIOFUEL ENERGY CORP.
Sign-up for BioFuel Energy Receives Proposal For A Possible Transaction investment picks
DENVER , Aug.
Sign-up for BioFuel Energy Reports Second Quarter 2013 Results investment picks
2013/11/11
DENVER , Nov.
Sign-up for BioFuel Energy Reports Third Quarter 2013 Results investment picks
DENVER , Nov.
Sign-up for BioFuel Energy Statement On Announced Definitive Agreement investment picks
2013/11/25
DENVER , Nov.
Sign-up for BioFuel Energy Statement On Announced Sale Of Plants investment picks
2014/1/31
By Claudia Assis, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of biofuels maker Solazyme Inc. rallied 12% on Friday after the company said it started commercial operations at two facilities in Iowa, with products being sold and distributed in the U.S. and Brazil.
Sign-up for Biofuel maker Solazyme up 12%, announces commercial ops investment picks
By Jacob Bunge Ethanol producers' share prices took a hit Friday after the U.S. government proposed trimming the yearly mandates for the biofuel in gasoline, raising questions about demand for a fuel source that has been a boon to the nation's farm economy.
Sign-up for Biofuel Stocks Sag As U.S. EPA Eyes Lower Ethanol Mandate investment picks
2013/11/22
By Ben Fox Rubin Biotechnology firm Biogen Idec Inc. (BIIB) said the European Medicines Agency's Committee for Medicinal Products for Human Use determined that dimethyl fumarate in its drug Tecfidera qualifies as a new active substance.
Sign-up for Biogen Gains Positive EU Determination for MS Drug; Shares Jump investment picks
2014/1/29
Biogen Idec Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2013 results, including revenue of $6.9 billion, a 26% increase compared to the prior year.
Sign-up for Biogen Idec 2013 Total Revenues Increase 26 Percent to $6.9 Billion investment picks
2013/10/28
Biogen Idec Inc.'s (BIIB) third-quarter earnings climbed 22% as sales for its multiple sclerosis treatment Tecfidera boosted the biotechnology company's revenue.
Sign-up for Biogen Idec 3rd-Quarter Profit Up 22% investment picks
2013/10/28
By Nathalie Tadena Biogen Idec Inc.'s (BIIB) third-quarter earnings climbed 22% as sales for its multiple sclerosis treatment Tecfidera boosted the biotechnology company's revenue.
Sign-up for Biogen Idec 3rd-Quarter Profit Up 22% on Tecfidera Sales, Lifts Outlook investment picks
--Biogen Idec and Isis to leverage antisense technology to accelerate discovery and development of novel therapies--
Sign-up for Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders investment picks
2013/12/17
Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn’s disease.
Sign-up for Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe investment picks
2014/1/9
--Partnership to Focus on Developing Novel Therapies for Sickle Cell Disease and Beta-Thalassemia--
Sign-up for Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies investment picks
2014/4/10
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of ELOCTATE ™ , an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe hemophilia A.
Sign-up for Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate™ (rFVIIIFc) for Hemophilia A investment picks
2014/1/30
Biogen Idec (NASDAQ: BIIB) and UCB (Euronext: UCB) announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Sign-up for Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia investment picks
Biogen Idec (NASDAQ: BIIB) today announced that it has been added to the prestigious Dow Jones Sustainability World Index (DJSI World) – becoming the first and only U.S. based biotech sector firm to make the list.
Sign-up for Biogen Idec Becomes First U.S.-Based Biotech Named to Dow Jones Sustainability World Index investment picks
Biogen Idec (NASDAQ: BIIB) will present new data from its hemophilia clinical development and research programs at the 55 th Annual Meeting of the American Society of Hematology (ASH) , taking place in New Orleans, December 7-10.
Sign-up for Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting investment picks
2014/3/28
The U.S. Food and Drug Administration has approved Biogen Idec Inc.'s treatment for hemophilia B, a largely inherited disorder that is the second-most common type of hemophilia.
Sign-up for Biogen Idec Hemophilia B Treatment Approved investment picks
2014/4/10
Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adam M.
Sign-up for Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer investment picks
2013/12/2
Biogen Idec (NASDAQ:BIIB) announced today that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application (BLA) for ALPROLIX™, the company’s investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.
Sign-up for Biogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™ investment picks
2014/3/18
Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application (BLA) for marketing approval of PLEGRIDY™, a subcutaneous pegylated interferon candidate for relapsing forms of multiple sclerosis (RMS). The PDUFA date has been extended by three months, which is the standard extension period.
Sign-up for Biogen Idec Receives Notification of PDUFA Date Extension for Plegridy™ (Peginterferon Beta-1a) investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference to Biogen Idec Receives Notification of PDUFA Date Extension for Plegridy™ (Peginterferon Beta-1a)
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity